IP Library Granted Patent US 8,263,760
Granted Patent B2
US 8,263,760 · App. 12/852,057 · Granted Sep 11, 2012

Methods and means for treating DNA repeat instability associated genetic disorders

Assignee: Prosensa Holding BV
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,760
App. No.
12/852,057
Granted
Sep 11, 2012
Kind
B2
Abstract

The current invention provides for methods and medicaments that apply an oligonucleotide comprising aninosine and/or an uracile and/or a nucleotide containing a base able to form a wobble base pair, said oligonucleotide being preferably RNAse H substantially independent and being complementary only to a repetitive sequence in a human gene transcript, for the manufacture of a medicament for the diagnosis, treatment or prevention of a cis-element repeat instability associated genetic disorders in humans. The invention hence provides a method of treatment for cis-element repeat instability associated genetic disorders. The invention also pertains to a modified oligonucleotide which can be applied in a method of the invention to prevent the accumulation and/or translation of repeat expanded transcripts in cells.

Claims (8)

1. An oligonucleotide comprising an inosine, wherein said oligonucleotide consists of a sequence that is complementary to a repetitive sequence selected from the group consisting of (CAG)n, (GCG)n, (CUG)n, (CGG)n, (GAA)n, (GCC)n and (CCUG)n, and is 9 to 50 nucleotides long.

2. An oligonucleotide according to claim 1 , consisting of a sequence that is complementary to a repetitive sequence selected from the group consisting of (CAG)n, (GCG)n, (CUG)n, (CGG)n, (GAA)n, (GCC)n and (CCUG)n, wherein the oligoucleotide is 9 to 50 nucleotides long and wherein the oligonucleotide is a RNAse H substantially independent oligonucleotide.

3. An oligonucleotide according to claim 1 , wherein said oligonucleotide comprises a radioactive label or fluorescent label.

4. An oligonucleotide according to claim 2 , wherein said oligonucleotide comprises a radioactive label or fluorescent label.

5. A pharmaceutically acceptable composition comprising an oligonucleotide as defined in any one of claims 1 to 4 and at least one excipient and/or targeting ligand for delivery of the oligonucleotide to the cell and/or enhancing the intracellular delivery of the oligonucleotide.

6. A nucleic acid vector capable of conferring expression of an oligonucleotide as defined by any one of claims 1 to 4 in human cells.

7. An oligonucleotide according to any one of claims 1 - 4 , wherein the oligonucleotide consists of (CIG) 7 and is a 2′-O-methyl RNA phosphorothioate oligonucleotide.

8. The nucleic acid vector of claim 6 , wherein said vector is a viral vector.

Assignments (4)
CHANGE OF NAME Recorded Sep 30, 2015
From: PROSENSA TECHNOLOGIES B.V.
To: BIOMARIN TECHNOLOGIES B.V.
Reel/Frame 036732/0042 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2014
From: PROSENSA HOLDING N.V.
To: PROSENSA TECHNOLOGIES B.V.
Reel/Frame 034115/0924 →
CHANGE OF NAME Recorded Nov 2, 2014
From: PROSENSA HOLDING B.V.
To: PROSENSA HOLDING N.V.
Reel/Frame 034115/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2010
From: DE KIMPE, JOSEPHUS JOHANNES; PLATENBURG, GERARDUS JOHANNES
To: PROSENSA HOLDING BV
Reel/Frame 025347/0993 →
Priority Claims (1)
EP 08151228 · Feb 8, 2008 · regional
Continuity (2)
Continuation PCTNL2009050049 · Feb 5, 2009
Related Publication 20110184050A1 · Jul 28, 2011